Login to Your Account



Financings Roundup

Aragon's Series D Adds $50M To Advance ARN-509 in CRPC

By Catherine Shaffer
Staff Writer

Friday, October 5, 2012

Aragon Pharmaceuticals Inc. parlayed its successful Phase II results in prostate cancer to a new financing round worth $50 million supported by existing investors and led by new investor venBio. The funds will support advancement of ARN-509 in castration-resistant prostate cancer (CRPC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription